The Technical Analyst
Select Language :
Advicenne SA [ADVIC.PA]

Exchange: EURONEXT Industry: Biotechnology

Advicenne SA Price, Forecast, Insider, Ratings, Fundamentals & Signals

Advicenne SA is listed at the  Exchange

0.00% €6.50

America/New_York / 31 des 1970 @ 19:00


RATING 2021-04-23
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/192/203/224/221/232/23
Revenuen/an/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebitn/an/an/an/an/a
Asset n/an/an/an/an/a
Debtn/an/an/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -3.67 | sector: PE 17.68
PE RATIO: COMPANY / INDUSTRY
0x
Company: PE -3.67 | industry: PE -7.48
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

€ 0 - 0

( +/- 0.00%)
ATR Model: 14 days
Profile picture for
            Advicenne SA

ADVIC.PA

Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.

Last 10 Buy Signals

Date Signal @
RETHUSDMay 19 - 18:243 416.02
^NZ50May 19 - 18:00PTS11 667
TETUSDMay 19 - 18:1811.95
XFUNDUSDMay 19 - 18:11389.57
CAHUSDMay 19 - 18:1121.33
YAKUSDMay 19 - 18:09515.82
DAIUSDMay 19 - 18:00$0.998
OHMUSDMay 19 - 17:4412.14
MEDIAUSDMay 19 - 17:4319.74
CTXUSDMay 19 - 17:454.37

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.